应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
EMA Emera Inc.
交易中 08-28 09:32:36 EDT
50.02
+0.00
0.00%
最高
50.02
最低
50.02
成交量
178.00
今开
50.02
昨收
50.02
日振幅
0.00%
总市值
152.95亿
流通市值
152.95亿
总股本
3.06亿
成交额
8,905
换手率
0.00%
流通股本
3.06亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
伯维(ABBV)向EMA递交Skyrizi克罗恩病治疗上市申请
金吾财讯 · 08-27 16:56
伯维(ABBV)向EMA递交Skyrizi克罗恩病治疗上市申请
中化国际EMA项目投产
智通财经 · 08-25
中化国际EMA项目投产
Emera(EMA)上半年调整后净利润增至6.27亿加元、净收入降至6.67亿加元
金吾财讯 · 08-07
Emera(EMA)上半年调整后净利润增至6.27亿加元、净收入降至6.67亿加元
财报前瞻|Emera Inc.本季度营收预计增15.89%,机构观点偏谨慎
财报Agent · 07-31
财报前瞻|Emera Inc.本季度营收预计增15.89%,机构观点偏谨慎
瑞博生物-B:核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准
智通财经 · 07-28
瑞博生物-B:核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准
Rocket Lab股价站稳200日EMA上方:获NASA合同后是否值得买入?
环球市场播报 · 06-29
Rocket Lab股价站稳200日EMA上方:获NASA合同后是否值得买入?
恒瑞医药(600276.SH):瑞维鲁胺片上市许可申请获EMA受理
智通财经 · 06-22
恒瑞医药(600276.SH):瑞维鲁胺片上市许可申请获EMA受理
财报前瞻|Emera Inc.本季度营收预计增35.49%,盈利质量成看点
财报Agent · 05-01
财报前瞻|Emera Inc.本季度营收预计增35.49%,盈利质量成看点
罗氏获欧洲监管机构反馈后,启动Elevidys基因疗法新研究
环球市场播报 · 04-16
罗氏获欧洲监管机构反馈后,启动Elevidys基因疗法新研究
港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格
智通财经 · 04-01
港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格
和誉-B(02256):FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格,用于治疗肝细胞癌
智通财经 · 03-31
和誉-B(02256):FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格,用于治疗肝细胞癌
韩国与新加坡启动自贸协定升级谈判并签署核电合作备忘录
核电网 · 03-03
韩国与新加坡启动自贸协定升级谈判并签署核电合作备忘录
百奥泰:Usymro(乌司奴单抗注射液)获得英国 MHRA 上市批准
格隆汇 · 03-03
百奥泰:Usymro(乌司奴单抗注射液)获得英国 MHRA 上市批准
加载更多
公司概况
公司名称:
Emera Inc.
所属市场:
NYSE
上市日期:
--
主营业务:
Emera Inc.于1998年7月23日在加拿大注册成立,是一家北美能源服务提供商,拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州,并在加拿大大西洋省、新墨西哥州和加勒比地区增加了业务。Emera总部位于新斯科舍省哈利法克斯,其业务战略侧重于对其受监管的公用事业、卓越运营和效率进行持续投资,以便为其270万客户可靠地提供能源。公司在受监管公用事业的盈利机会取决于净投资规模、资本结构权益和目标回报,这些都是通过监管建立起来的。
发行价格:
--
{"stockData":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":50.02,"timestamp":1787923802419,"preClose":50.02,"halted":0,"volume":178,"delay":0,"changeRate":0,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"交易中","change":0,"latestTime":"08-28 09:32:36 EDT","open":50.02,"high":50.02,"low":50.02,"amount":8905.34,"amplitude":0,"askPrice":50.37,"askSize":200,"bidPrice":50.09,"bidSize":700,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787947200000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":50.02,"dividendRate":0.042158,"postHourTrading":{"tag":"盘后","latestPrice":50.02,"preClose":50.02,"latestTime":"17:43 EDT","volume":131170,"amount":6570757.23978,"timestamp":1787867037642,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.06855,"impliedVol":0.1888,"impliedVolPercentile":0.5498},"requestUrl":"/m/hq/s/EMA","defaultTab":"news","newsList":[{"id":"2662639772","title":"伯维(ABBV)向EMA递交Skyrizi克罗恩病治疗上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639772","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662639772?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:56","pubTimestamp":1787821007,"startTime":"0","endTime":"0","summary":"Skyrizi此前已经在银屑病、银屑病关节炎等多个自身免疫疾病领域拿到欧洲地区的获批资质,如若本次克罗恩病适应症顺利获批,将进一步拓宽该产品在欧洲炎症性肠病赛道的市场空间。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0472753341.HKD","LU0965508806.USD","LU1236620750.USD","TRUH","LU0985320562.USD","IE00BLSP4239.USD","LU0198837287.USD","LU0661504455.SGD","LU2125909593.SGD","LU0058720904.USD","LU2089283258.USD","IYH","RXL","FHLC","LU2125909247.SGD","PPH","SG9999011175.SGD","LU2133065610.SGD","JDOC","SG9999001440.SGD","IPOS","IXJ","LU0417517546.SGD","VHT","LU0289739699.SGD","LU1839511570.USD","LU1267930573.SGD","LU1732799900.SGD","LU0882574055.USD","FTXH","LU2023251221.USD","LU0234572021.USD","LU0114720955.EUR","LU1989771016.USD","LU2087621335.USD","GLAM","LU1236620834.HKD","BK4559","EMA","IE000F7OJYX1.SGD","XLV","IE0004445239.USD","LU1585245621.USD","LU0128525929.USD","LU2237443622.USD","AGNG","MEDX","PJP","BK4533","ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200130","title":"中化国际EMA项目投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662200130?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:09","pubTimestamp":1787623784,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648031","title":"Emera(EMA)上半年调整后净利润增至6.27亿加元、净收入降至6.67亿加元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648031","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657648031?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:34","pubTimestamp":1786102483,"startTime":"0","endTime":"0","summary":"金吾财讯 | 北美能源巨头Emera 公布2026年第二季度及上半年财务业绩。2026年二季度,Emera实现调整后净利润2.12亿加元,较上年同期的2.36亿加元有所放缓;净利润为1.05亿加元。2026年上半年,公司调整后净利润达到6.27亿加元,高于2025年上半年的6.15亿加元。期内净收入为6.67亿加元,低于去年同期的7.18亿加元。展望未来,公司预计,2026年调整后每股收益增长将超越其5%-7%的年度目标区间高位,公司重申截至2030年维持5%-7%的复合年均增长承诺。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148281703","title":"财报前瞻|Emera Inc.本季度营收预计增15.89%,机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1148281703","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148281703?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:42","pubTimestamp":1785458557,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年08月07日盘前发布第二季度财报,市场预期营收增长而利润承压,投资者关注盈利质量与现金流稳定性。一致预期显示,本季度Emera Inc.营收为20.29亿加元,同比增长15.89%;调整后每股收益为0.49加元,同比下降24.17%;EBIT为4.73亿加元,同比增长1.23%,上一季度未披露针对本季度的明确量化指引。上季度公司实现营收28.13亿加元,同比增长5.12%;毛利率50.20%;归属于母公司股东的净利润5.82亿加元,净利率20.69%;调整后每股收益同比增长7.00%,净利润环比增长568.97%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻|Emera Inc.本季度营收预计增15.89%,机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001188","title":"瑞博生物-B:核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654001188?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:59","pubTimestamp":1785239982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["EMA","IBBJ","IBBQ","BK4081","MDTX","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037238","title":"Rocket Lab股价站稳200日EMA上方:获NASA合同后是否值得买入?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037238","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647037238?lang=zh_cn&edition=full","pubTime":"2026-06-29 21:09","pubTimestamp":1782738540,"startTime":"0","endTime":"0","summary":"Rocket Lab股价周一盘前交易时段上涨,此前该公司宣布将收购卫星通信运营商Iridium,交易价值约80亿美元。这一消息叠加近期获得的NASA发射合同,为股价提供了技术面支撑。 从技术走势来看,Rocket Lab股价在6月25日跌至80.69美元的低点后获得支撑,目前盘前交易于90美元附近,成功站稳200日指数移动平均线上方。 上周,NASA宣布选择Rocket Lab执行三项Electron火箭发射任务,用于PolSIR和TSIS-2科学任务,预计于2027年初启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-29/doc-inifauhn5315358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0217","BK4081","EMA","300785","NASA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409710","title":"恒瑞医药(600276.SH):瑞维鲁胺片上市许可申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645409710?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:38","pubTimestamp":1782117505,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司收到了欧洲药品管理局(European Medicines Agency,简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请,这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT),治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","BK0060","BK0188","LU0359201885.HKD","LU1023057109.AUD","LU2580892789.USD","LU2097828805.USD","LU2148510915.USD","LU0405327494.USD","LU1781817850.SGD","LU2488822045.USD","BK0196","LU1580142542.USD","LU2495084118.USD","LU1146622755.USD","01276","LU2289578879.USD","LU0359202008.SGD","LU1820825898.SGD","BK0012","LU2097828557.USD","LU1997245094.SGD","LU2097828631.EUR","LU1969619763.USD","EMA","BK0183","LU2328871848.SGD","LU1255011170.USD","LU2097828714.EUR","LU0405327148.USD","LU1997244956.HKD","BK1191","LU1064130708.USD","LU1997245177.USD","LU1328615791.USD","LU2580892862.HKD","LU1064131003.USD","LU2097828474.EUR","BK4081","BK0028","BK0239","LU1655091616.SGD","LU2543165471.USD","600276","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185761853","title":"财报前瞻|Emera Inc.本季度营收预计增35.49%,盈利质量成看点","url":"https://stock-news.laohu8.com/highlight/detail?id=1185761853","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185761853?lang=zh_cn&edition=full","pubTime":"2026-05-01 08:17","pubTimestamp":1777594630,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年05月08日公布最新季度业绩,市场关注营收增速与成本控制的落地情况。根据一致预期,本季度Emera Inc.营收预计为30.09亿加元,同比增长35.49%;调整后每股收益预计为1.15加元,同比增长15.55%;息税前利润预计为7.02亿加元,同比增长7.05%;当前一致预期未提供本季度毛利率及净利润或净利率的具体预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Emera Inc.本季度营收预计增35.49%,盈利质量成看点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213629","title":"罗氏获欧洲监管机构反馈后,启动Elevidys基因疗法新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213629","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627213629?lang=zh_cn&edition=full","pubTime":"2026-04-16 20:44","pubTimestamp":1776343440,"startTime":"0","endTime":"0","summary":"罗氏公司周四宣布,在收到欧洲药品监管机构的反馈后,将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症,由罗氏与美国 Sarepta Therapeutics 公司合作研发。此前,因两例患者死亡事件与该疗法相关而引发审查,这款药物去年未能获得欧洲药品管理局的批准。Elevidys 目前已在 9 个国家获批用于可自主行走、确诊携带 DMD 基因突变的男孩,其中包括美国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhuszrw2800982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624593383?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上,和誉宣布,其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格,用于治疗肝细胞癌。目前,依帕戈替尼正在全球多地开展临床研究,此次获EMA授予ODD,将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外,依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定,以及中国国家药品监督管理局授予的突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","BK4585","BK4081","BK4588","LU2778985437.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2488822045.USD","VXUS","BK1161","EMA","LU2476274308.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和誉-B(02256):FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格,用于治疗肝细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2623581546?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B 发布公告,公司附属公司上海和誉生物医药科技有限公司宣布,其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格,用于治疗肝细胞癌。目前,依帕戈替尼正在全球多地开展临床研究,此次获EMA授予ODD,将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4081","LU2476274308.USD","LU2488822045.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","EMA","IE00B5MMRT66.SGD","LU2778985437.USD","02256","BK1161","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616376696","title":"韩国与新加坡启动自贸协定升级谈判并签署核电合作备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2616376696","media":"核电网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616376696?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:22","pubTimestamp":1772533330,"startTime":"0","endTime":"0","summary":"近日,韩国总统李在明对新加坡进行了国事访问,两国就升级韩-兴自由贸易协定及核电合作达成重要共识。韩国产业通商资源部长官与新加坡贸工部代表于3月2日共同签署了《关于启动韩新自贸协定升级谈判的联合宣言》。与此同时,韩国水电与核电公司和新加坡能源市场厅也签署了关于小型模块化反应堆合作的谅解备忘录,这标志着韩国核电企业首次与新加坡政府机构在核电领域建立正式合作关系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303202141a69d90f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303202141a69d90f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NLR","EMA","BK4081","BK4606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616698376","title":"百奥泰:Usymro(乌司奴单抗注射液)获得英国 MHRA 上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616698376","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616698376?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:33","pubTimestamp":1772526786,"startTime":"0","endTime":"0","summary":"格隆汇3月3日丨百奥泰公布,公司于近日收到了英国药品和健康产品管理局签发的关于Usymro上市批准通知。截至本公告披露日,BAT2206已获得美国FDA、欧洲 EMA 和英国 MHRA 批准上市,美国注册商品名称为STARJEMZA,欧洲注册商品名称为 Usymro;已向中国 NMPA 递交上市许可申请,目前正在评审中。Usymro获得英国 MHRA 上市批准后可在英国进行销售,公司海外销售产品品类得到进一步扩充,将进一步提升公司产品的国际影响力,有望对公司长期经营业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163601a445ce72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163601a445ce72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emera.com","stockEarnings":[{"period":"1week","weight":-0.034},{"period":"1month","weight":-0.0815},{"period":"3month","weight":-0.041},{"period":"6month","weight":-0.0388},{"period":"1year","weight":0.0539},{"period":"ytd","weight":0.0158}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0408},{"period":"3month","weight":0.0193},{"period":"6month","weight":0.1241},{"period":"1year","weight":0.1925},{"period":"ytd","weight":0.1308}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emera Inc.于1998年7月23日在加拿大注册成立,是一家北美能源服务提供商,拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州,并在加拿大大西洋省、新墨西哥州和加勒比地区增加了业务。Emera总部位于新斯科舍省哈利法克斯,其业务战略侧重于对其受监管的公用事业、卓越运营和效率进行持续投资,以便为其270万客户可靠地提供能源。公司在受监管公用事业的盈利机会取决于净投资规模、资本结构权益和目标回报,这些都是通过监管建立起来的。","exchange":"NYSE","name":"Emera Inc.","nameEN":"Emera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emera Inc.,EMA,Emera Inc.股票,Emera Inc.股票老虎,Emera Inc.股票老虎国际,Emera Inc.行情,Emera Inc.股票行情,Emera Inc.股价,Emera Inc.股市,Emera Inc.股票价格,Emera Inc.股票交易,Emera Inc.股票购买,Emera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}